Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Operating Leases (2018 - 2025)

Corbus Pharmaceuticals Holdings has reported Operating Leases over the past 6 years, most recently at $3.2 million for Q4 2023.

  • For Q4 2023, Operating Leases fell 30.72% year-over-year to $3.2 million; the TTM value through Dec 2023 reached $3.2 million, down 30.72%, while the annual FY2023 figure was $3.2 million, 30.72% down from the prior year.
  • Operating Leases for Q4 2023 was $3.2 million at Corbus Pharmaceuticals Holdings, down from $3.6 million in the prior quarter.
  • Over five years, Operating Leases peaked at $8.6 million in Q1 2020 and troughed at $3.2 million in Q4 2023.
  • A 5-year average of $6.2 million and a median of $6.4 million in 2021 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: skyrocketed 488.51% in 2019 and later plummeted 30.72% in 2023.
  • Year by year, Operating Leases stood at $8.1 million in 2019, then fell by 12.4% to $7.1 million in 2020, then decreased by 16.03% to $6.0 million in 2021, then fell by 21.5% to $4.7 million in 2022, then plummeted by 30.72% to $3.2 million in 2023.
  • Business Quant data shows Operating Leases for CRBP at $3.2 million in Q4 2023, $3.6 million in Q3 2023, and $4.0 million in Q2 2023.